BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

New research demonstrates faster COVID-19 recovery with metabolic activator treatment

July 21, 2021 | News

Treatment with the metabolic activators improved liver health and decreased the levels of inflammation

Metabolic activators were found to reduce recovery time by as many as 3.5 days in patients with mild-to-moderate Covid-19, according to a Swedish-British study published in *Advanced Science*. The researchers also found that treatment with the metabolic activators improved liver health and decreased the levels of inflammation, as shown by inflammatory markers.

Conducted by researchers at Science for Life Laboratory at KTH Royal Institute of Technology in Stockholm, in collaboration with the Sahlgrenska Academy in Gothenburg and King's College, London, the human phase three clinical study showed that patients with mild-to-moderate Covid-19--who were also receiving standard care--experienced a 3.5-day reduction in recovery time when receiving the combination of metabolic activators, nicotinamide riboside (NR), L-serine, N-acetyl-L-cysteine (NAC), and L-carnitine tartrate. All four activators are aimed at improving mitochondrial function. The results of the study build on findings from phase two clinical data.

"Our phase three clinical data shows that metabolic activators significantly improve the recovery, liver health, and markers of inflammation of patients with COVID-19," says the study's lead author, Adil Mardinoglu, professor at KTH and Kings College and research fellow at Science for Life Laboratory.

"Dysfunctional mitochondria have been implicated in worsened progression for Covid-19, and we are pleased to find that the combination of these metabolic activators helps to remedy the stress put on the body of an infected patient."